Gibson Dunn Advised Damora Therapeutics On Sale To Galecto And On $285 Million Private Placement By Galecto

Gibson Dunn Advised Damora Therapeutics On Sale To Galecto And On $285 Million Private Placement By Galecto

Gibson Dunn is advised privately held biotechnology company Damora Therapeutics, Inc. on its sale to Galecto, Inc.

Gibson Dunn also advised on a concurrent $285 million private placement by Galecto. Jefferies, Leerink Partners, UBS, and LifeSci are serving as the placement agents to Galecto.

The Gibson Dunn corporate team includes Ryan Murr (Partner), Branden Berns (Partner), and Evan Shepherd (Associate), Maggie Zhang (Associate), Chad Kang (Associate), Anika Gidwani (Associate). Melanie Neary (Partner), and Nick Linke (Associate), Lauren Navarro (Associate), advised on public company matters; Gina Hancock (Partner), and Lucy Hong (Associate), advised on employee compensation and benefits matters; Pamela Lawrence Endreny (Partner), and Ryan Rott (Associate), advised on tax matters.

Click to know more about Gibson Dunn & Crutcher LLP

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.